Psychedelics
Psychedelics Company Havn Life Announces Commencement of Public Trading on the CSE
Havn Life Sciences Inc. (CSE:HAVN) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that it has commenced trading on the Canadian Securities Exchange (“CSE”) under the ticker symbol “HAVN”. “Listing on the Canadian Securities […]
Field Trip Psychedelics Inc. Introduces Trip, a Mobile App Designed to Expand Your Mind
Field Trip Psychedelics Inc. (“Field Trip” or the “Company”), the company redefining mental health and well-being through its ground-breaking work in psychedelics and psychedelic-enhanced psychotherapy, today announced the launch of its first-ever app, Trip. A first-of-its-kind app and experience, Trip allows people from anywhere in the world to access tools that support self-exploration and consciousness […]
Aion Therapeutics Files Five Patents with the United States Patent and Trademark Office
Aion Therapeutic Inc. (CSE: AION) (“Aion Therapeutic” or the “Company“) is pleased to announce that the Company has filed five patent applications with the United States Patent and Trademark Office (USPTO) pertaining to new treatments combining healing compounds in medical cannabis with healing compounds from mushrooms (edible and psychedelic), and other natural plants known for their […]
VANCOUVER, British Columbia, September 8th, 2020 – Apotheca Systems Inc. (“Apotheca” or “the Company”), an applied AI for evidence based natural medicines company with an emphasis on AI assistance for cannabis and psychedelic based therapy, is pleased to announce the next development phase of its patent pending AI Assisted Personalized Therapy Framework Platform, Apotheca.ai. With […]
September 08, 2020 08:45 ET | Source: Ehave The Licensing Agreement advances Ehave’s mission to make medical records more portable. MIAMI, Sept. 08, 2020 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today it has entered into a licensing agreement to license a complete […]
HAVN Life Sciences Announces Completion of Acquisition Transaction
VANCOUVER, BC / ACCESSWIRE / September 4, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (the “Company” or “Havn Life”), is pleased to announce that it has successfully completed its acquisition of HAVN Research Inc. (“HAVN Research“), acquiring 100% of the outstanding shares of HAVN Research (the “Acquisition Transaction“). HAVN Research is a biotechnology company engaged in […]
September 3, 2020 DENVER, Colorado, USA, September 3, 2020 — Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine”, “MIG” or the “Company”) is pleased to announce that its shareholders have agreed to extend lock-up restrictions in respect to 35,737,460 shares of the Company that were due to be released on September 6, 2020, for an additional 120 […]
Numinus Announces Filing of Final Short Form Prospectus for Offering of up to $4,000,000
VANCOUVER, BC, Sept. 3, 2020 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies, is pleased to announce it has filed a final short form prospectus (the “Prospectus“) dated September 1, 2020 in connection with its previously announced […]
MagicMed Industries Inc. hat im Rahmen einer überzeichneten Privatplatzierung rund 1,6 Millionen US-Dollar gesammelt, um die Psybrary ™ zu entwickeln – eine eigene Plattform zur Wirkstoffforschung für die Psychedelika-Industrie. Mit seiner umfassenden Expertise in molekularen Derivaten möchte das Unternehmen eine Bibliothek von Derivatvarianten entwickeln, die Partner zu Therapeutika entwickeln können. Schauen wir uns genauer an, […]
MagicMed Raises $1.6M to Launch Psychedelic Drug Discovery Platform
MagicMed Industries Inc. raised roughly $1.6 million in an oversubscribed private placement to develop Psybrary™—a proprietary drug discovery platform for the psychedelics industry. Using its deep expertise in molecular derivatives, the company aims to develop a library of derivative variant molecules that partners can develop into therapeutics. Let’s take a closer look at why […]
CALGARY, AB, Sept. 2, 2020 /CNW/ – MagicMed Industries Inc. (“MagicMed” or the “Company“) is pleased to announce that it has completed, and oversubscribed, its previously announced brokered private placement (the “Offering“) for gross proceeds of $1,642,880. Pursuant to the Offering, the Company issued 6,571,520 new common shares at a price of $0.25 per common share. The Company now has 20,111,520 […]
Mind Medicine Australia has submitted Australia’s first applications to the Therapeutic Goods Administration (TGA) to reschedule Psilocybin and MDMA so that they can be more easily used as part of clinical therapies for the treatment of major classes of mental illness. The rescheduling would move these medicines from Schedule 9 of the Uniform Scheduling of […]
Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the company redefining mental health and well-being through its ground-breaking work in psychedelics and psychedelic-enhanced psychotherapy, today announced it has closed the first tranche of its Series B financing (the “Financing“), raising gross proceeds of $11.0M from a broad base of investors. The Financing was completed through […]
Champignon Brands Inc. (CSE: SHRM) (the “Company” or “Champignon”) is expanding its rapid-onset treatment service for major depressive disorder (“MDD”). Champignon will offer esketamine for the treatment of adults with MDD at its flagship clinic starting in September 2020. Ketamine was declared a breakthrough treatment for depression by the US Food and Drug Administration (“FDA”). […]
Today, ATAI Life Sciences (“ATAI” or the “Company”), a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of EmpathBio, a wholly-owned subsidiary developing derivatives of 3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD) and other indications. PTSD is a chronic condition characterized by recurring and intrusive thoughts […]
Novamind Appoints Dr. Reid Robison as Chief Medical Officer
Novamind Ventures Inc. (“Novamind“), a mental health and wellness company specialized in psychedelic-assisted psychotherapy, is pleased to announce that Reid Robison, MD, MBA, has been appointed Chief Medical Officer (“CMO“) of Novamind. Dr. Robison co-founded Cedar Psychiatry LLC and Cedar Clinical Research LLC, organizations that were acquired by Novamind in July 2019. Dr. Robison is […]
Numinus Files Restated Financial Reports
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI) announces that as a result of a review by the Company’s auditors in connection with its recently announced prospectus, the Company, on August 24, 2020, has filed restated financial statements (the “Amended Financial Statements”) together with a restated management’s discussion and analysis (together with the Amended Financial […]
Cybin Corp.: A Diversified Play on Psychedelic Therapeutics
More than 700 million people around the world suffer from a mental illness, addiction or eating disorder, according to the World Health Organization, which costs the global economy $2.5 trillion each year in direct and indirect costs. Despite these significant costs, large pharmaceutical companies have stopped searching for the next Prozac. Psychedelics, including psilocybin, […]
Full Spectrum: The Next Revolution in Extraction
The cannabis industry has rapidly matured over the past few years as legalization has swept North America and other parts of the world. While cannabis flower and distillates dominated the early market, patient and consumer preferences have shifted toward higher-quality products that provide more benefits—such as full-spectrum cannabis oils. Let’s take a look at the […]
Warum Sie in psychedelische „Plattform-Plays“ investieren sollten
Die Psychedelika-Industrie hat im vergangenen Jahr ein enormes Wachstum verzeichnet. Zusätzlich zu regulatorischer Unterstützung und Entkriminalisierung sind viele Unternehmen entweder an die Börse gegangen oder haben Kapital aufgenommen, und Investoren haben eine wachsende Anzahl von Optionen, um ihr Portfolio aufzubauen – es gibt sowohl Möglichkeiten im Produkt- als auch Plattformbereich. Lassen Sie uns einen Blick […]
MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD
MindMed is funding a Phase 1 Clinical Trial at University Hospital Basel Liechti Lab NEW YORK, Aug. 25, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines and the University Hospital Basel’s Liechti Lab are now combining MDMA and LSD in a groundbreaking Phase 1 clinical trial. The Phase […]
Why You Should Invest in Psychedelic ‘Platform Plays’
The psychedelics industry has experienced tremendous growth over the past year. In addition to regulatory support and decriminalization, many companies have either gone public or raised capital and investors have a growing number of options when it comes to building exposure into their portfolio—including both product and platform opportunities. Let’s take a look at […]
Tim Ferriss, Mental Health Contributors Bring Psychedelic Research into the Mainstream; Fund Final Research Toward FDA Approval of MDMA-Assisted Psychotherapy as Treatment for PTSD MEDIA CONTACT: media@maps.org GENERAL QUESTIONS: askmaps@maps.org Having raised $30 million in non-profit donations in less than six months, the Multidisciplinary Association for Psychedelic Studies (MAPS) and the Psychedelic Science Funders Collaborative (PSFC) today announced the […]
Ehave Announces Plans to Accelerate the Monetization of its Proprietary Digital Health Platform
The Ehave Dashboard utilizes BlockChain technology to provide better communication among health care providers for better patient outcomes and is compliant with both HIPAA and GDPR standards. MIAMI, Aug. 24, 2020 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to healthcare patients, announced today […]
NeonMind Ready to Launch Four Mushroom Coffee Blends
Better Plant Sciences Inc. (CSE:PLNT) (OTCQB:BOSQF) (FE:YG3) (“Better”) announces that subsidiary Neonmind Biosciences (“NeonMind”) has completed final product development for four unique Ayurveda-inspired and botanical-enhanced mushroom coffee blends which are now moving into the mixing stage with a co-packer. The coffees are fair trade and organic, with Ayurvedic organic botanicals and organic mushroom extracts. Each is […]
Nutritional High Completes Acquisition of Psychedelic Science Corp
Toronto, Ontario–(Newsfile Corp. – August 17, 2020) – Nutritional High International Inc. (CSE: EAT) (“Nutritional High” or the “Company“) is pleased to announce that that it has completed the previously announced acquisition (the “Transaction“) of Psychedelic Science Corp.(“PSC“), as per our press release dated June 1, 2020. PSC develops health and wellness products while performing research […]
Beckley Psytech appoints renowned psychedelic experts to Scientific Advisory Board
Beckley Psytech, the psychedelic medicine company, has appointed a series of respected figures from the psychiatric and psychedelic research fields to its Scientific Advisory Board, bringing decades of expertise to its research programme. The new appointees include: Professor Guy Goodwin, Senior Research Fellow at the Department of Psychiatry, The University of Oxford Dr Robin L. […]
Being Facilitated Under a Schedule 1 Health Canada Dealer’s License DENVER, Colorado, USA, August 18, 2020 — Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine™” or the “Company”) is pleased to announce it is the first organization to exercise its cGMP(₁) capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade psilocybin, […]
What Are Functional Mushrooms?
Most people think of white buttons at the grocery store when they think of mushrooms, but in reality, there are hundreds of different kinds of mushrooms. Functional mushrooms—like functional foods and beverages—are mushroom varieties that provide a health benefit, ranging from run-of-the-mill vitamins and minerals to important nutrients, including selenium, potassium, riboflavin, niacin, proteins, […]
Tryp Therapeutics Inc. (“Tryp” or the “Company”), a clinical-stage pharmaceutical company developing therapeutics targeting diseases with high unmet medical needs, announced today it has entered into an agreement with Albany Molecular Research Inc. (“AMRI”), a leading global contract research, development and manufacturing organization, to provide research, development and cGMP manufacturing of a proprietary psilocybin active […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]
Relevium is a publicly-traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution.
Jacksam/Convectium designs and markets proprietary automated vape, POD and cartridge filling/capping equipment for the cannabis industry.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
